Bristol Names Sigal To Head R&D Following Death Of James Palmer
Executive Summary
Bristol-Myers Squibb Pharmaceutical Research Institute President Elliott Sigal, MD, is taking the helm of Bristol's R&D efforts effective immediately, the company announced Oct. 28
You may also be interested in...
Bristol Is Not Bayer: Primary Care Strategy Is “Different, Not Exit”
Bristol-Myers Squibb is trying a "different model" for primary care, but the company has no intention of exiting the market, CEO Peter Dolan told the Bear Stearns conference in New York Sept. 13
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials